Press release
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023
SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA
About this update from Arcturus Therapeutics Holdings Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nArcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2023 after the market close on Tuesday, May 9 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 9, 2023.\n\n\nArcturus Therapeutics First Quarter 2023 Earnings Conference Call\n\n\n\nTuesday, May 9, 2023 @ 4:30 p.m. ET\n\n\n\nDomestic: 1-888-886-7786\n\n\n\nInternational: 1-416-764-8658\n\n\n\nConference ID: 70942720\n\n\n\nWebcast: Link\n\n\n\nAbout Arcturus Therapeutics\n\n\nFounded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230426005037/en/\n\nIR and Media Contacts\nArcturus Therapeutics\nNeda Safarzadeh\nVP, Head of IR/PR/Marketing\n(858) 900-2682\[email protected]\n\nKendall Investor Relations\nCarlo Tanzi, Ph.D.\n(617) 914-0008\[email protected]\n\n\nSource: Arcturus Therapeutics Holdings Inc.","length":5110,"tagName":"div"}]